Avidity Biosciences, Inc (NASDAQ:RNAM) — Market Cap & Net Worth
Market Cap & Net Worth: Avidity Biosciences, Inc (RNAM)
Avidity Biosciences, Inc (NASDAQ:RNAM) has a market capitalization of $11.02 Billion ($11.02 Billion) as of May 2, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2086 globally and #759 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Avidity Biosciences, Inc's stock price $71.34 by its total outstanding shares 154478871 (154.48 Million). Analyse RNAM operating cash flow to see how efficiently the company converts income to cash.
Avidity Biosciences, Inc Market Cap History: 2026 to 2026
Avidity Biosciences, Inc's market capitalization history from 2026 to 2026. Data shows growth from $11.02 Billion to $11.02 Billion (0.00% CAGR).
Avidity Biosciences, Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Avidity Biosciences, Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of RNAM by Market Capitalization
Companies near Avidity Biosciences, Inc in the global market cap rankings as of May 2, 2026.
Key companies related to Avidity Biosciences, Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Avidity Biosciences, Inc Historical Marketcap From 2026 to 2026
Between 2026 and today, Avidity Biosciences, Inc's market cap moved from $11.02 Billion to $ 11.02 Billion, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $11.02 Billion | -- |
End of Day Market Cap According to Different Sources
On May 2nd, 2026 the market cap of Avidity Biosciences, Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $11.02 Billion USD |
| MoneyControl | $11.02 Billion USD |
| MarketWatch | $11.02 Billion USD |
| marketcap.company | $11.02 Billion USD |
| Reuters | $11.02 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more